• Lora Stanka Kirigin Biloš, Velimir Altabas, Andrea Vukić Dugac, and Maja Baretić.
• Department of Endocrinology, Diabetes and Metabolic Diseases "Mladen Sekso", University Hospital Centre "Sestre Milosrdnice", 10000 Zagreb, Croatia.
• Medicina (Kaunas). 2024 Mar 14; 60 (3).

AbstractCystic fibrosis-related diabetes (CFRD) is the most common comorbidity in patients with cystic fibrosis (CF). CFRD has been correlated with important clinical outcomes, including poor nutrition, reduced pulmonary function, and earlier mortality. However, clinical decline due to abnormalities of blood glucose (dysglycemia) begins early in CF, before the diagnosis of CFRD by the gold-standard oral glucose tolerance test (OGTT). Continuous glucose monitoring (CGM) has been validated in patients with CF and has been recognized as a valuable tool in detecting early glucose abnormalities in patients with CF. Several CGM parameters have been used to predict CFRD in some but not all studies, and there is no consensus regarding CGM use for diagnostic purposes. Thus, it remains a complementary test to OGTT in CFRD diagnosis. The aim of this review is to provide an update on the pathophysiological mechanisms of CFRD, recent advances in the use of CGM for CFRD screening, and the association between CGM measures and CF-related clinical outcomes.

12 keywords...

hide…